Search results
ASCO: J&J's radioligand spurs responses, but 4 deaths mar early results
FierceBiotech· 3 days agoJohnson & Johnson’s radiopharmaceutical spurred “profound and durable” responses, however, four...
Lilly partners with Aktis, deepening radiopharma investment
BioPharma Dive via Yahoo Finance· 6 days agoNectin-4 is also a popular target of antibody-drug conjugates, another type of cancer mecine. Under...
Is Vaginal Estrogen Safe in Breast Cancer Survivors?
Medscape· 5 days agoVaginal estrogen therapy appears to be safe after early breast cancer in patients with HR-negative tumors and those with HR-positive tumors concurrently...
AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Dive via Yahoo Finance· 6 days agoAstraZeneca expects to launch 20 new drugs over the target time period, which it measures as starting in November 2022. The company has launched six...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 6 days agoThose proteins, CD3 and CD19, are also the targets of one of the oldest approved bispecific...
Pfizer expands cost cuts with new $1.5B target
BioPharma Dive via Yahoo Finance· 5 days agoThe company, which previously announced plans to trim $4 billion in spending by the end of 2024, aims to save another $1.5 billion over the next three...
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
Zacks via Yahoo Finance· 3 days agoSales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent...
Swiss Market Ends Slightly Higher
RTT News· 4 days agoThe Switzerland market ended slightly up on Thursday after spending much of the day's session fairly well above the flat line. Investors assessed the latest batch of European economic data, reacted to earnings and other corporate updates.
SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca
BioPharma Dive via Yahoo Finance· 5 days agoThe company is making antibody drugs that, like some others in development, target so-called activin...
Boston radiopharmaceuticals startup inks deal worth up to $1.16B with Lilly - Boston Business...
The Business Journals· 6 days agoA Boston radiopharmaceuticals startup that is already backed by three Big Pharma companies now has a...
